ADDERALL XR 15
Clinical safety rating: caution
Comprehensive clinical and safety monograph for ADDERALL XR 15 (ADDERALL XR 15).
ADDERALL XR contains a mixture of amphetamine salts, including dextroamphetamine and levoamphetamine. The mechanism of action involves increasing synaptic levels of dopamine and norepinephrine by inhibiting their reuptake and enhancing their release from presynaptic terminals, leading to CNS stimulation.
| Metabolism | Amphetamine is primarily metabolized in the liver via cytochrome P450 enzymes, including CYP2D6, to various oxidative and deaminated metabolites. Aromatic hydroxylation produces p-hydroxyamphetamine and p-hydroxynorephedrine. Some metabolism also occurs via monoamine oxidase (MAO). |
| Excretion | Renal: approximately 90% of a dose is excreted in urine, with about 30% as unchanged amphetamine and the remainder as metabolites including deaminated and oxidized products; fecal excretion accounts for less than 10%. |
| Half-life | The terminal elimination half-life of amphetamine in adults is approximately 10-13 hours; in children, it is slightly shorter (6-8 hours). For the l-amphetamine isomer, the half-life is 9-11 hours. The extended-release formulation provides a prolonged duration of effect due to a biphasic release profile. |
| Protein binding | Amphetamine is approximately 20% bound to plasma proteins, primarily albumin. |
| Volume of Distribution | Volume of distribution for amphetamine is about 3-4 L/kg, indicating extensive tissue distribution. The large Vd contributes to the long terminal half-life. |
| Bioavailability | Oral bioavailability of amphetamine from ADDERALL XR is approximately 90-100% relative to an oral solution; the extended-release formulation has a bioavailability similar to immediate-release tablets when administered orally. |
| Onset of Action | Oral (ADDERALL XR): Onset of clinical effect is typically within 1-2 hours post-dose, corresponding to the initial immediate-release component of the formulation. |
| Duration of Action | Duration of clinical effect for ADDERALL XR is approximately 8-12 hours, due to the combination of immediate-release and delayed-release beads, providing a smooth therapeutic effect throughout the day. |
| Molecular Weight | 368.86 |
Oral, 20-60 mg once daily in the morning; initial dose 20 mg once daily, titrated by 10-20 mg weekly based on tolerability and efficacy.
| Dosage form | CAPSULE, EXTENDED RELEASE |
| Renal impairment | GFR 15-30 mL/min: reduce dose by 50%; GFR <15 mL/min: use with caution, maximum dose 30 mg daily; hemodialysis: not recommended. |
| Liver impairment | Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: not recommended. |
| Pediatric use | Children 6-12 years: initial 10 mg once daily, increase by 5-10 mg weekly up to 30 mg/day; adolescents 13-17 years: initial 10 mg once daily, increase by 10 mg weekly up to 40 mg/day. |
| Geriatric use | Start at 10 mg once daily, increase slowly by 5-10 mg every 2 weeks; monitor cardiovascular status and cognitive function; consider lower maintenance doses (20-30 mg daily) due to increased sensitivity. |
| 1st trimester | Amphetamines are associated with increased risk of cardiovascular malformations and oral clefts when used during the first trimester. Use only if potential benefit justifies risk. |
| 2nd trimester | May cause fetal growth restriction, prematurity, and withdrawal symptoms. Use only if clearly needed. |
| 3rd trimester | Exposure near term may lead to neonatal withdrawal symptoms including dysphoria, agitation, and significant lassitude. Avoid use during third trimester. |
Clinical note
Comprehensive clinical and safety monograph for ADDERALL XR 15 (ADDERALL XR 15).
| Placental transfer | Amphetamine and dextroamphetamine cross the placenta. Fetal serum concentrations are approximately 40-60% of maternal levels. |
| Breastfeeding | Amphetamine is concentrated in breast milk and may cause irritability, poor feeding, and weight loss in nursing infants. The American Academy of Pediatrics recommends avoiding use during breastfeeding. If used, monitor infant for agitation and insomnia. |
■ FDA Black Box Warning
WARNING: ABUSE, MISUSE, AND ADDICTION. ADDERALL XR has a high potential for abuse, which can lead to tolerance, dependence, and serious cardiovascular or psychiatric adverse events. Misuse may cause sudden death or serious cardiovascular events.
| Common Effects | Eye irritation Burning eyes Eye discomfort Eye itching Eye pain |
| Serious Effects |
Hypersensitivity to amphetamine or other sympathomimetic aminesConcurrent use of MAO inhibitors or within 14 days of discontinuationHistory of drug abuseSymptomatic cardiovascular diseaseModerate to severe hypertensionHyperthyroidismGlaucomaAgitated states
| Precautions | Serious cardiovascular events including sudden death, stroke, and myocardial infarction have been reported in patients with pre-existing structural cardiac abnormalities or other serious heart problems., Blood pressure and heart rate should be monitored, increased risk of hypertension and tachycardia., May exacerbate psychiatric disorders including pre-existing psychosis, mania, or bipolar disorder; emergence of new psychotic or manic symptoms., Long-term suppression of growth in children; monitor growth during treatment., Risk of serotonin syndrome when co-administered with serotonergic drugs., Risk of seizures in patients with a history of seizures., Visual disturbances including difficulty with accommodation and blurred vision. |
Loading safety data…
| Lactation Rating | L3 - Moderately Safe (or Avoid, though L3 is commonly used) |
| Teratogenic Risk | Pregnancy Category C. First trimester: Possible increased risk of congenital malformations (cardiac, orofacial clefts) based on limited human data; amphetamines shown to cause developmental toxicity in animal studies. Second/third trimester: Risk of premature delivery, low birth weight, neonatal withdrawal syndrome (irritability, feeding difficulties). |
| Fetal Monitoring | Monitor maternal blood pressure and heart rate, weight gain, fetal growth (ultrasound), and signs of preterm labor. Assess neonatal adaptation post-delivery. |
| Fertility Effects | Amphetamines may impair male/female fertility via hormonal alterations (e.g., decreased prolactin, altered gonadotropins). Resolution after discontinuation expected but not guaranteed. |
| Food/Dietary | Avoid high-fat meals as they delay absorption and reduce peak concentration. Avoid acidic foods (e.g., citrus fruits, cola, vinegar) close to dosing, as they may decrease absorption. Do not consume alcohol while taking Adderall XR. |
| Clinical Pearls | Adderall XR 15 is a once-daily extended-release formulation of amphetamine salts. Monitor for cardiovascular events; check blood pressure and heart rate at baseline and periodically. Avoid use in patients with structural cardiac abnormalities, cardiomyopathy, or serious arrhythmias. Use with caution in patients with a history of substance abuse. Do not crush or chew capsules; sprinkle contents on applesauce if needed. Onset of action is 1-2 hours with duration of 10-12 hours. |
| Patient Advice | Take exactly as prescribed; do not increase dose without consulting your doctor. · Swallow capsule whole; do not crush or chew. If needed, open capsule and sprinkle contents on a spoonful of applesauce, swallow immediately without chewing. · Avoid taking late in the day to prevent insomnia. · Common side effects include decreased appetite, trouble sleeping, dry mouth, and headache. · This drug has a high potential for abuse and dependence; keep in a safe place. · Report any signs of heart problems: chest pain, shortness of breath, fainting. · Monitor growth in children; height and weight should be checked during treatment. |